微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 73.57% | 1.29% | 0.46% | 24/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 73.23% | -5.08% | -0.71% | 28/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 73.76% | -5.42% | 0.85% | 26/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 73.14% | -5.91% | 0.69% | 27/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 72.64% | -3.02% | -5.85% | 28/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 77.15% | -0.8% | -1.08% | 29/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 77.99% | -0.38% | 0.33% | 27/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 77.74% | -0.39% | 3.78% | 27/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 74.91% | -5.3% | -3.69% | 29/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 77.78% | -0.93% | -0.66% | 25/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 78.29% | -0.97% | 0.31% | 26/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 78.05% | -0.91% | -1.33% | 28/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 79.1% | 2.16% | 0.76% | 25/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 78.5% | 4.88% | -0.7% | 28/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 79.06% | 6.25% | 0.38% | 22/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 78.76% | 7.91% | 1.73% | 23/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 77.42% | 12.83% | 3.44% | 21/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 74.85% | 10.93% | 0.59% | 30/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 74.41% | 12.71% | 1.94% | 27/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 72.99% | 14.39% | 6.38% | 28/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 68.62% | 8.81% | 1.69% | 30/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 67.48% | 13.2% | 2.21% | 42/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 66.02% | 12.07% | 3.46% | 32/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 63.81% | 10.92% | 1.19% | 42/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 63.06% | 11.24% | 5.78% | 37/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 59.61% | 14.78% | 1.19% | 55/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 58.91% | 19.63% | 2.41% | 44/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.52% | 17.25% | 1.48% | 49/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 56.69% | 17.51% | 9.15% | 46/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 51.94% | 1.12% | 5.47% | 61/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 49.24% | 2% | 0.37% | 48/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 49.06% | -2.33% | -4.48% | 50/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 51.36% | -0.66% | 2.25% | 48/159 | 48.44% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 50.23% | -3.52% | 4.12% | 36/159 | 46.2% | 贝达药业 | 95.58% | 行业排名> |
| 2016-03-31 | 48.24% | 2% | -6.69% | 27/159 | 43.5% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 51.7% | -0.51% | -0.7% | 38/159 | 46.24% | 微芯生物 | 97.46% | 行业排名> |
| 2015-06-30 | 52.06% | 2% | 0.19% | 31/159 | 45.36% | 贝达药业 | 97.01% | 行业排名> |